Relay Therapeutics (RLAY)
(Delayed Data from NSDQ)
$3.53 USD
-0.12 (-3.29%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $3.52 -0.01 (-0.28%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Relay Therapeutics, Inc. has a market cap of $625.77M, which represents its share price of $3.65 multiplied by its outstanding shares number of 171.45M. As a small-cap company, RLAY's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
RLAY 3.53 -0.12(-3.29%)
Will RLAY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RLAY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RLAY
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
RLAY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?
Other News for RLAY
Relay Therapeutics: What's Next For H2 2025?
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights ...
Relay Therapeutics has positive read from Celcuity data, says Barclays
Claire Mazumdar Joins Relay Therapeutics as Director
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors | RLAY Stock News